Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by TD Asset Management Inc

TD Asset Management Inc cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 32.3% in the 2nd quarter, Holdings Channel reports. The firm owned 149,084 shares of the biopharmaceutical company’s stock after selling 71,276 shares during the period. TD Asset Management Inc’s holdings in Ultragenyx Pharmaceutical were worth $6,127,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RARE. Van ECK Associates Corp lifted its stake in Ultragenyx Pharmaceutical by 34.0% during the fourth quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 400 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Ultragenyx Pharmaceutical by 44.6% during the fourth quarter. Victory Capital Management Inc. now owns 10,565 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 3,259 shares during the last quarter. Natixis Advisors L.P. lifted its stake in Ultragenyx Pharmaceutical by 10.8% during the fourth quarter. Natixis Advisors L.P. now owns 15,289 shares of the biopharmaceutical company’s stock valued at $731,000 after purchasing an additional 1,496 shares during the last quarter. Amalgamated Bank lifted its stake in Ultragenyx Pharmaceutical by 10.0% during the fourth quarter. Amalgamated Bank now owns 15,716 shares of the biopharmaceutical company’s stock valued at $752,000 after purchasing an additional 1,427 shares during the last quarter. Finally, M&T Bank Corp acquired a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $310,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on RARE shares. Wedbush upped their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Robert W. Baird raised their price objective on shares of Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a research note on Friday, May 31st. Stifel Nicolaus raised their price objective on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. Wells Fargo & Company raised their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.43.

Insider Activity

In other news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the transaction, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 40,675 shares of company stock worth $2,149,446. 5.80% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Trading Down 0.1 %

Ultragenyx Pharmaceutical stock opened at $55.72 on Wednesday. The company has a market capitalization of $5.14 billion, a P/E ratio of -7.00 and a beta of 0.56. The firm’s fifty day simple moving average is $49.15 and its 200-day simple moving average is $46.04. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $58.73.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 35.7% on a year-over-year basis. During the same quarter last year, the firm earned ($2.25) EPS. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.